These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37942906)

  • 1. Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective.
    Pan X; Wang L; Liu J; Earp JC; Yang Y; Yu J; Li F; Bi Y; Bhattaram A; Zhu H
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S65-S77. PubMed ID: 37942906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases.
    Li RJ; Ma L; Li F; Li L; Bi Y; Yuan Y; Li Y; Xu Y; Zhang X; Liu J; Bhattaram VA; Wang J; Schuck R; Pacanowski M; Zhu H
    J Clin Pharmacol; 2022 Dec; 62 Suppl 2():S27-S37. PubMed ID: 36461744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.
    Moore KT; Zannikos PN; Masters JC; Willmann S; Shen J; Frost C
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S78-S84. PubMed ID: 37942912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic.
    Xiong Y; Fan J; Kitabi E; Zhang X; Bi Y; Grimstein M; Yang Y; Earp JC; Zheng N; Liu J; Wang Y; Zhu H
    Clin Pharmacol Ther; 2022 Mar; 111(3):572-578. PubMed ID: 34807992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An AI Approach to Generating MIDD Assets Across the Drug Development Continuum.
    Barrett JS; Goyal RK; Gobburu J; Baran S; Varshney J
    AAPS J; 2023 Jul; 25(4):70. PubMed ID: 37430126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.
    Wang Y; Zhu H; Madabushi R; Liu Q; Huang SM; Zineh I
    Clin Pharmacol Ther; 2019 Apr; 105(4):899-911. PubMed ID: 30653670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework.
    Langevin B; Gobburu JVS; Gopalakrishnan M
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S48-S64. PubMed ID: 37942905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective.
    Li RJ; Ma L; Kim H; Kim I; Hanes L; Altepeter T; Lee J; Liu J; Zhu H; Wang Y
    AAPS J; 2022 Jul; 24(4):79. PubMed ID: 35790574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feeding the critically ill obese patient: a systematic review protocol.
    Secombe P; Harley S; Chapman M; Aromataris E
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):95-109. PubMed ID: 26571286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.
    Rizk ML; Bhavnani SM; Drusano G; Dane A; Eakin AE; Guina T; Jang SH; Tomayko JF; Wang J; Zhuang L; Lodise TP
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.
    Antwi F; Fazylova N; Garcon MC; Lopez L; Rubiano R; Slyer JT
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-14. PubMed ID: 27820152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inclusion of Subjects who are Obese in Drug Development: Current Status and Opportunities.
    Vaidyanathan J; Fletcher EP; Ramamoorthy A; Madabushi R; Burckart GJ
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S10-S17. PubMed ID: 37942907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.